Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Infection
68%
Hematologic Malignancy
32%
Diseases
27%
Invasive Aspergillosis
23%
Bloodstream Infection
19%
Systemic Mycosis
17%
Antiinfective Agent
17%
Amphotericin B
16%
Neutropenia
15%
Mycosis
13%
Mould
13%
Aspergillus
13%
Antifungal Therapy
12%
Mucormycosis
12%
Infectious Agent
12%
Posaconazole
11%
Antibiotics
11%
Cytomegalovirus
11%
Chemotherapy
11%
Cytomegalovirus Infection
10%
Antifungal Agent
10%
Caspofungin
9%
Voriconazole
9%
Candida
9%
Hepatitis C Virus
9%
Vancomycin
8%
Leukemia
8%
Pseudomonas aeruginosa
7%
Immunocompromised Patient
7%
Clinical Trial
7%
Adverse Event
7%
Fluconazole
7%
Candidemia
6%
Acute Myeloid Leukemia
6%
Aspergillosis
6%
Aspergillus fumigatus
5%
Neoplasm
5%
Monotherapy
5%
Immune Checkpoint Inhibitor
5%
Hepatitis C
5%
Escherichia coli
5%
Imipenem
5%
Virus Infection
5%
Diarrhea
5%
Combination Therapy
5%
Ciprofloxacin
5%
Daptomycin
5%
Solid Malignant Neoplasm
5%
Bacterial Infection
5%
Medicine and Dentistry
Infection
68%
Malignant Neoplasm
61%
Hematologic Malignancy
25%
Antiinfective Agent
22%
Transplantation
19%
Catheter Infection
19%
Bloodstream Infection
18%
Mycosis
18%
Hematopoietic Cell
18%
Central Venous Catheter
15%
Neutropenia
15%
Diseases
14%
Systemic Mycosis
14%
Cytomegalovirus
12%
Cytomegalovirus Infection
11%
Antifungal Therapy
11%
Mucormycosis
11%
COVID-19
11%
Pathogen
11%
Hematopoietic Stem Cell Transplantation
11%
Cell Transplantation
10%
Invasive Aspergillosis
10%
Diagnosis
10%
Antibiotics
9%
Infectious Disease
8%
Aspergillus
8%
Immunocompromised Patient
8%
Hepatitis C Virus
8%
In Vitro
7%
Cohort Effect
7%
Outpatient
7%
Cancer
7%
Minocycline
6%
Antibiotic Therapy
6%
Clinical Trial
6%
Blood Culture
5%
Aspergillosis
5%
Cancer Treatment
5%
Acute Myeloid Leukemia
5%
Candidemia
5%
Immunosuppressive Treatment
5%
Amphotericin B
5%
Health Care Cost
5%
Bacterial Infection
5%
Keyphrases
Cancer Patients
40%
In Cancer
24%
Patients with Cancer
23%
Hematological Malignancies
21%
Invasive Aspergillosis
13%
Risk Factors
11%
Central Venous Catheter
11%
Neutropenia
9%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Antimicrobial
9%
Invasive Fungal Infection
9%
Cytomegalovirus Infection
9%
Bacteremia
9%
Neutropenic Patients
9%
Voriconazole
8%
Cytomegalovirus
8%
Catheter-related Bloodstream Infection (CRBSI)
8%
Posaconazole
8%
In Vitro Activity
8%
Mucormycosis
8%
Haematopoietic Stem Cell Transplant Recipients
7%
Catheter
7%
Antifungal Therapy
7%
Bloodstream Infection
7%
Cancer Center
6%
Caspofungin
6%
Minocycline
6%
Fungal Infection
6%
Liposomal Amphotericin B
6%
Invasive Pulmonary Aspergillosis
6%
Leukemia
6%
Neutropenic
6%
Amphotericin B
6%
Acute Myeloid Leukemia
6%
Immunocompromised Patients
6%
Catheter-related
6%
Virulence
6%
Vancomycin
5%
Hepatitis C Virus
5%
Triazole
5%
Hematopoietic Stem Cell Transplantation
5%
Antibiotics
5%
Confidence Interval
5%
Clinical Outcomes
5%
Infectious Diseases
5%
Cancer Treatment
5%
Hematopoietic Cell Transplantation
5%